कंपनी का अवलोकन
Anbio Biotechnology operates within the healthcare sector, specifically focusing on the medical instruments and supplies industry by providing in vitro diagnostics (IVD) products across a wide geographical footprint that includes the European Union, Asia Pacific, North America, South America, Africa, and international markets. The company's core offerings encompass SARS-CoV-2 antigen rapid tests, combined SARS-CoV-2 and influenza A/B antigen rapid tests, as well as lateral flow immunoassay and fluorescence immunoassay technologies for diagnostic applications. This entity maintains a market capitalization of $1.13B and reported a trailing twelve-month revenue of $6.92M while employing a workforce of 27 individuals. These valuation and revenue figures indicate that the company holds a significant market capitalization relative to its reported annual sales, suggesting a high multiple on revenue that reflects market expectations for future growth or intangible asset value rather than current cash flow generation.
वित्तीय स्वास्थ्य
The company reported a revenue of $6.92M and a net income of $2.57M for the trailing twelve months, while EBITDA data is not available for this reporting period. The substantial difference between the $6.92M in revenue and the $2.57M in net income reveals a highly efficient cost structure with minimal overhead, as evidenced by the company's ability to retain a large portion of top-line sales as bottom-line profit. Regarding cash flow flexibility, free cash flow figures are not disclosed in the available financial data, which limits the immediate assessment of operational cash generation but does not preclude the possibility of positive underlying cash dynamics. The gross margin stands at 89.7%, the operating margin is 73.4%, and the profit margin is 37.2%, indicating that the company retains nearly 90% of revenue after direct costs and over 70% after operating expenses. The balance sheet presents a conservative profile with $13.43M in cash holdings against $0 in debt, and the debt-to-equity ratio is not applicable due to the absence of debt. This liquidity position is further supported by a current ratio of 211.10, which indicates an exceptionally strong ability to meet short-term obligations with current assets. Management effectiveness is highlighted by a return on equity of 11.2% and a return on assets of 4.7%, demonstrating that the company generates a robust return on shareholder capital despite the high valuation multiples.
मूल्यांकन आकलन
The trailing twelve-month P/E ratio is 430.83, whereas the forward P/E ratio is not available, implying that market participants are pricing in significant future earnings growth or that current earnings do not fully reflect the company's potential trajectory. The price-to-book ratio is recorded at 41.16, which indicates a substantial market premium over the company's book value, suggesting that the market values the firm significantly higher than the net assets would suggest on a liquidation basis. Additionally, the price-to-sales ratio stands at 163.95, and the EV/EBITDA multiple is not available, meaning these alternative valuation metrics suggest the market is placing a very high value on every dollar of sales generated relative to typical industry standards. The stock has traded within a range defined by a 52-week high of $55.65 and a 52-week low of $5.89, and without the current specific share price, the exact percentage position within this range cannot be calculated from the provided facts alone, though the wide spread indicates high volatility. The beta value is not available in the provided data, which prevents a direct quantification of the stock's price volatility relative to the broader market movements.
Growth & Income
The company experienced a revenue growth of -21.6% year-over-year, while earnings growth stood at 2.8% year-over-year, indicating that earnings are currently growing faster than revenue, a scenario often seen when cost reductions outpace sales declines or when one-time gains boost the bottom line. As a non-dividend payer, the company does not distribute a dividend yield, and the payout ratio is 0.0%, meaning that the company retains all of its earnings rather than distributing them to shareholders. This reinvestment strategy implies that the management team directs profits back into the business operations, potentially funding research and development for new diagnostic products or market expansion efforts. Overall, the growth and income profile is characterized by declining top-line revenue coupled with positive earnings growth and a complete retention of profits, reflecting a capital allocation strategy focused on internal growth rather than shareholder income distributions.